Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pathologic analysis of 63 cases of brain metastases from lung was reported. The specimens of all cases were labelled by 4 antibodies (HLC3-AB, CEA, Keratin, GFAP), by means of ABC method. According to our data, brain metastases from lung accounted for 50.4% of whole brain metastases. Lobus frontalis was the most common intracranial metastatic site of lung cancer. Four histopathological types were classified: adenocarcinoma (55.6%), undifferentiated carcinoma (17.4%), adenosquamous carcinoma (14.3%) and squamous cell carcinoma (12.7%). The immunohistochemical results showed that HLC3-AB is a helpful marker in identifying brain metastases from lung cancer. GFAP showed negative in malignant cells but positive in stroma. This result suggested that the stroma of brain metastases contains ingredients originating from astro-gliofibre.
 ...
PMID:[Pathological and immunohistochemical study on 63 cases of brain metastases from the lung]. 147 84

The SHIN-3 cell line producing CA125 was established from an ovarian cancer patient. Using the SHIN-3 cell line, we found that the low-molecular-mass antigen (about 50 KDa) might be the main antigenic determinant in CA125-immunoreactive species. A new monoclonal antibody to this low-molecular-mass was raised to examine a new cancer associated antigen by a hybridoma technique. Using enzyme linked immuno sorbent assay, ten clones were selected from among 398 clones. Two clones were IgG1 and eight were IgM. By immunostaining (ABC assay), a new antibody (named SH-9) reacted with normal pulmonary bronchus and uterine cervical glands. No positivity, however, was observed in endometriosis (adenomyosis). In tumorous lesions of ovary, SH-9 antibody reacted specifically with mucinous cystadenoma-benign, borderline or malignant. However, no positivity was found in serous cystadenocarcinoma. In any other carcinomas, only lung cancer (adenocarcinoma, squamous cell carcinoma) showed a clear positivity. Immuno blotting analysis showed that SH-9 antibody recognized a low molecular mass. Therefore, SH-9 is seen to be an extremely unique antibody when compared with OC125 biochemically and histochemically.
 ...
PMID:[A new monoclonal antibody (SH-9) recognizes the low molecular mass of ovarian cancer antigen CA125]. 169 12

Spleen cells of BALB/c mice immunized with human pulmonary adenocarcinoma cell LTEP-a2 were fused with murine myeloma cell SP 2/0, from which 4 hybridomas (2 A7, 2 E9, 4 F2 and 5 F11) were obtained. Indirect immunofluorescence test showed that these 4 monoclonal antibodies reacted with human lung cancer cells, but not with 2 BS or the lymphocytes and red blood cells in 4 different ABO groups of 10 persons. Using ABC immunoperoxidase stain technique, these 4 antibodies showed negative reaction with 9 tissue types from the normal subject and fetus but could react with 52-83% of the 29 human lung carcinomas and 64-92% of the 24 non-small cell lung cancers (non-SCLC). When 5 F11 was combined with 2 A7 or 2 E9, the percentage of positive stain was 100% in 24 non-SCLC. The results of indirect immunofluorescence stain showed that strong membrane stain by 5 F11 and membrane stain by 4 F2 were obtained, indicating that these antibodies could recognize antigens on cancer cell membrane. It is suggested that a mixture of 5 F11 and other antibodies be useful in the diagnosis and treatment of lung cancer. Molecular weight of the antigens recognized by the 4 antibodies was determined by SDS-PAGE and immunoblot technique to be 47 KD (2 A7), 67 KD (2E9), 40 KD (4F2) and 56 KD (5 F11).
 ...
PMID:[Monoclonal antibody against human lung carcinoma]. 217 66

Recently Ge et al reported LAC-122, LAC-210 and LAC-163 McAbs against Human non-small cell lung cancer and LSC McAbs against human lung small cell carcinoma. The immunotoxin, composed of McAb LAC-122 conjugated with Ricin A chain has been reported to have the significant cytotoxic effect in vitro on lung adenocarcinoma cell line SPC-A-1 by Tan et al. The LAC-122 alone has no effect on this target cell in the presence of complement from human, rabbit or guinea pig. The tumor associated antigens of human lung cancer have been recognized for many years, but only few reports deal with the common antigens or common epitopes of the lung cancer. From one fusion, 20 hybrids had been observed, all of these culture supernatants could react with target cell by IF. One of them after 4 th cloning, immunoglobulin isotype of the monoclonal antibody thus far obtained belonged to IgM and named to LC-1. Table 1 showed the results of ABC staining of LC-1 with a variety of tumors, normal adult and fetal tissues. From 12 non-small cell lung cancers, including 7 lung adenocarcinoma, 2 lung squamous carcinoma, 3 lung giant cell carcinoma, only one adenocarcinoma gave negative staining. As for 6 small cell lung cancers, all of them showed the positive reaction. It could be also reacted with 11 other tumors.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[McAb LC-1 against human lung cancer]. 255 85

A monoclonal antibody (MoAb), MLuC1, derived from the fusion of P3-X63-Ag 8-U1 mouse myeloma cells with spleen cells from an HR mouse immunized with the carcinoma cell line SW626, was studied to define its reactivity profile on normal and neoplastic human tissues and its potential clinical applications in lung cancer. Evaluation of paraffin sections using the ABC immunoperoxidase method showed a "pan-epithelial" reactivity; a large majority of epithelial components of organs in the respiratory, digestive and urogenital systems (except liver, rectum and ovary) were immunostained. As regard to neoplastic tissues MLuC1 recognized 84% of lung carcinomas (82% of small cell, 100% of squamous cell, 74% of adenocarcinomas), 86% of breast and 62% of ovarian carcinomas. On the contrary, MLuC1 was non-reactive with the other normal and tumoral non-epithelial tissues. Due to its spectrum of reactivity this MoAb could be useful for different diagnostic purposes such as differential diagnosis and lung cancer cytology.
 ...
PMID:Histopathological characterization of a novel monoclonal antibody, MLuC1, reacting with lung carcinomas. 284 84

The effect of cloned human interferon-alpha (IFN-alpha) on the expression of HLA-ABC antigens (HLA-ABC) and beta 2-microglobulin (beta 2m) on human peripheral lymphoid cells in vivo was studied by cytofluorometry using monoclonal antibodies and fluorescein-labelled rabbit anti-mouse immunoglobulin. A significant increase in the mean fluorescence intensity of HLA-ABC (median 59%, P less than 0.001) and beta 2m (median 57%, P less than 0.001) on small lymphoid cells was observed 24 h after initiation of IFN-alpha treatment (50 X 10(6) units IFN-alpha/m2 three times a week). The enhanced expression of these antigens in vivo was found in 11 of 12 examined patients with primary bronchial carcinoma. A concomitant increase in serum beta 2m (median 90%, P less than 0.001) was found in all patients. In contrast the amount of cell-associated HLA-ABC and beta 2m remained unchanged (P greater than 0.1 and P greater than 0.5, respectively) by day-to-day analysis of an untreated healthy control group. An increased expression of both HLA-ABC (mean 55%, P less than 0.0005) and beta 2m (mean 23%, P less than 0.01) was also observed prior to treatment in the lung cancer patients when compared to a group of age matched healthy individuals. Treatment with IFN-alpha caused a significant redistribution of mononuclear cells resulting in both absolute and relative lymphopenia. Pre-treatment lymphocyte counts were 1.09 X 10(9)/1 (range 0.49-1.73), post-treatment counts were 0.55 X 10(9)/1 (range 0.39-1.06).
 ...
PMID:Enhanced expression in vivo of HLA-ABC antigens and beta 2-microglobulin on human lymphoid cells induced by human interferon-alpha in patients with lung cancer. Enhanced expression of class I major histocompatibility antigens prior to treatment. 298 11

Serum neuron-specific enolase (NSE) was measured in 23 patients with small cell lung cancer (SCLC) and 184 patients with non-small cell lung cancer (non-SCLC), both of which were untreated. Increased levels of serum NSE were observed in 82.6% (19/23) of SCLC, whereas 9.8% (18/184) of non-SCLC had positive results showing an overall positive rate of 17.9% (37/207) in lung cancer cases. In addition, the elevation of serum NSE levels in non-SCLC patients seemed to suggest poor prognosis. Elevated serum NSE levels returned to normal with either surgical resection of the tumor or response to chemotherapy, after which serum NSE levels were again raised to levels higher than the previous ones in cases of relapse or progression. The evaluation of serum NSE may be a useful marker for both diagnosis and monitoring of responsiveness to therapy as well as for recognition of relapse and progression in SCLC. Identification of NSE as assessed by immunohistochemical procedure employing the ABC method on formalin-fixed paraffin-embedded tissue sections in lung cancer cases of each histological type, showed that some materials from non-SCLC cases were positively stained despite the presence of normal serum NSE levels, and did not always parallel the serum levels. Among other various tumor markers determined, serum CA 19-9 had a relatively high positive rate of 38.2% (42/110) in adenocarcinoma of the lung.
 ...
PMID:[Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer]. 302 57

The cytochrome P450 (CYP) enzymes metabolize drugs and other xenobiotics in liver and also in some extrahepatic tissues. We have studied the expression and localization of CYP3A in primary lung tumours and normal lung tissue from the same patients. Thirty-two patients undergoing partial or total lung resection for therapy of primary pulmonary carcinoma were included in this study. Immunohistochemical staining for CYP3A was performed with a modification of the ABC technique. Eight of the 32 cases of primary pulmonary carcinoma showed expression of CYP3A. In 12 of the 32 cases of normal tissue, the seromucous glands were positive for CYP3A. The bronchial epithelium was positive for CYP3A in 11 cases. We observed no correlation between CYP3A expression in tumour tissue and that in seromucous glands or bronchial epithelium. We conclude that CYP3A is present in both normal and cancerous lung tissue. Our findings suggest, however, no co-expression of CYP3A in lung cancer.
 ...
PMID:Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. 773 77

The expression of tumour suppressor gene P53 products-P53 protein in patients with primary lung cancer has been studied by ABC immunohistochemical method using McAb 1801 as probe. Abnormalities in P53 expression were found in 63 of 78 carcinomas, 23 of 26 squamous cell carcinomas, 23 of 29 adenocarcinomas, 7 of 11 large cell carcinomas, 7 of 9 small cell carcinomas and all 3 cases of adenoid cystic carcinomas showing abnormal P53 expression, whereas no expression of P53 was detectable in 11 normal lung samples. These findings suggest that the pathogenesis of lung cancer may also be related with abnormalities of P53 gene.
 ...
PMID:[The immunohistochemical study of p53 protein in primary lung cancer]. 808 21

Serum tumor markers are useful for post-operative follow up, however, they are not necessarily useful for early stage diagnosis. Because the lesion is so small that it is unable to detect a tiny amount of their molecules in serum. If we could detect those antigens directly in cells from cytological specimens, it would provide a new diagnostic method for early stage cancers. The expression of carbohydrate antigens were examined with panel of specific anti-carbohydrate monoclonal antibodies (MAbs) on cytological specimens of sputum. In total, 146 sputa were collected in Sacomano's solution; 69 malignant cases (35 squamous cell carcinomas, 13 adenocarcinomas and 21 other primary lung cancers), 19 benign cases (pneumonia and bronchitis) and 58 borderline-malignancy cases which were defined by the standard of Japan Society of Lung Cancer. After removing mucus, the cells were stained with Vector's ABC method. Evaluation was performed by counting positively-stained cells among benign or atypical cells. As we examined previously in lung cancer tissue sections, there was statistical significance of frequency of positive stain between malignant and benign cases especially in MAbs AH6, THK2, SH1 and SNH3. Borderline malignancy gave intermediate value which means certain number of cells with cancerous biochemical character are mixed in the borderline specimens. In most cases, cell membrane was positively stained and sometimes, cytoplasm. Although the high sensitivity was observed in AH6 and SNH3, their specificity was lower than that of SH1, and visa versa. Those results indicate that the combination of anti-carbohydrate MAbs is useful for cytological diagnosis of lung cancer.
 ...
PMID:[Detection of carbohydrate antigens of malignant cells in sputum with panel of monoclonal antibodies]. 836 Oct 31


1 2 3 4 Next >>